[Lys(DOTA)(4)]BVD15, a novel and potent neuropeptide Y analog designed for Y-1 receptor-targeted breast tumor imaging

Department of Nuclear Medicine and Radiobiology, Centre d'Imagerie Moléculaire de Sherbrooke, Université de Sherbrooke, Québec, Canada.
Bioorganic & medicinal chemistry letters (Impact Factor: 2.65). 02/2010; 20(3):950-3. DOI: 10.1016/j.bmcl.2009.12.068
Source: PubMed

ABSTRACT We substituted a truncated neuropeptide Y (NPY) analog, [Pro(30), Tyr(32), Leu(34)]NPY(28-36)NH(2) also called BVD15, at various positions with DOTA (1,4,7,10-tetraazacyclododecane-1,4,7-10-tetraacetic acid) and evaluated the effect of the coupling position with the binding affinity for NPY Y(1) receptors (NPY1R). Our data suggest that [Lys(DOTA)(4)]BVD15 (K(i)=63+/-25 nM vs. K(i)=39+/-34 nM for BVD15) is a potent NPY analog suitable for radiolabeling with metallo positron emitters for PET imaging of breast cancer.

  • [Show abstract] [Hide abstract]
    ABSTRACT: In this work, a number of different process upgrades have been implemented at a 1 ton/h CO2 capture test facility operating on a slipstream of flue gas from a coal-fired power plant. The benefits of the upgrades have been assessed through tests using monoethanolamine (MEA) as well as novel solvents. Amongst others the solvent cross flow heat exchanger was improved resulting in a closer temperature approach. The improvement of the heat exchanger was found only to reduce the energy requirement marginally. It was furthermore found that applying inter-stage cooling in the lower section of the absorber did not benefit the MEA process significantly, whereas with novel solvents, the regeneration energy could be reduced with up to 7%. Introducing a vapour recompression cycle on the lean solvent loop was found to lower the regeneration energy with up to 20% with MEA but to a lesser extent with novel solvents. In all cases the introduction of vapour recompression significantly increased the auxiliary power consumption. All in all, a saving in the regeneration energy of close to 25% compared to that of the standard MEA process (3.7 GJ/ton CO2) could be realised with the tested process improvements and novel solvents.
    Energy Procedia 01/2011; 4:1558-1565. DOI:10.1016/j.egypro.2011.02.025
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neuropeptide Y (NPY) Y1 receptors are overexpressed in human breast carcinomas. They also have important functional roles in breast tumour growth and metastasis. This study investigates the synthesis of 15 truncated NPY analogues as models for Y1 receptor specific radiopharmaceuticals, using competition radioreceptor binding assays from brain tissue homogenates from Y2Y4-double knockout mice. These peptides are based on the previously reported BVD15 scaffold. Different measures to improve Y1 affinity and plasma metabolic stability were investigated. Extending from the previously reported [Lys(DOTA)4]BVD15 analogue, it was found that lysine4 is capable of tolerating various modifications, including prosthetic groups and other bifunctional chelators, but also that [Lys4]BVD15 has improved Y1 affinity, relative to BVD15 itself. Substitution of lysine4 for side chain shortened analogues retains Y1 receptor affinity of the analogues. Furthermore, modifications at the N-terminal isoleucine resulted in dramatic reduction of Y1 affinity.
    International Journal of Peptide Research and Therapeutics 01/2013; 19(1). DOI:10.1007/s10989-012-9330-z · 0.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The potent Y1 receptor antagonist, 1229U91 has an unusual cyclic dimer structure that makes syntheses of analogue series quite challenging. We have examined three new routes to the synthesis of such peptides that has given access to novel structural variants including heterodimeric compounds, ring size variants and labelled conjugates. These compounds, including a fluorescently labelled analogue VIII show potent antagonism that can be utilised in studying Y1 receptor pharmacology.
    Organic & Biomolecular Chemistry 04/2014; DOI:10.1039/c4ob00176a · 3.49 Impact Factor